Pharmaceuticals News 8 December 2025

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the

10 December 2025

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price

10 December 2025

Cancer Research · FDA Approvals · Investment Analysis · NYSE:GSK · Pharmaceuticals · Stock Market

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Note: This article is for informational purposes only and does not constitute investment advice. Merck stock recap: What happened on December 9, 2025? Merck & Co., Inc. (NYSE: MRK) closed Tuesday, December 9, 2025 at $96.89, down 2.06% on the

10 December 2025

After-Hours Trading · Keytruda · Merck · NYSE:MRK · Pharmaceuticals · Stock Market

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

HUNTSVILLE, Ala. — December 9, 2025 Eli Lilly and Company will invest more than $6 billion in a new advanced pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 high‑value permanent jobs and an estimated 3,000 construction jobs in what state

10 December 2025

Alabama · Business · Industry · Jobs · NYSE:LLY · Pharmaceuticals

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) has quietly turned into one of 2025’s wilder biotech stories: a tiny oncology name that’s run more than eightfold off its 52-week low, pulled back on a big equity raise, and now sits in the

9 December 2025

Financial News · Investment Analysis · NASDAQ:OLMA · Pharmaceuticals · Stock Forecast · Stock Market

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is ending 2025 in rare biotech air. The RNA interference (RNAi) specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a

9 December 2025

Biotech News · FDA Approval · Investing · NASDAQ:ARWR · Pharmaceuticals · Stock Market

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

As of 9 December 2025, GSK plc (LSE: GSK; NYSE: GSK) stock is trading close to its 52‑week highs on both sides of the Atlantic, after a year in which the UK pharma group has upgraded guidance, accelerated buybacks and

9 December 2025

Company Analysis · Financial News · Investment Strategies · NYSE:GSK · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company (NYSE: LLY) spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi

9 December 2025

Dividends · Earnings Reports · Investing · NYSE:LLY · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer Inc. (NYSE: PFE) is back in focus on December 8, 2025, as investors digest fresh clinical data in hemophilia, big strategic bets in obesity drugs, and an aggressive, AI‑driven cost‑cutting program – all while the stock continues to trade

8 December 2025

AI in Healthcare · Biotechnology · Financial News · NYSE:PFE · Pharmaceuticals · Stock Market

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase (BTK) degrader bexobrutideg (NX‑5948) in blood

8 December 2025

Biotech · Clinical Trials · Investment Analysis · Pharmaceuticals · Stock Market

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Published: December 8, 2025 – This article is for informational purposes only and is not financial advice. Key Takeaways JNJ Stock Today: Price, Performance and Dividend Johnson & Johnson (NYSE: JNJ) is trading around $202–203 per share in New York

8 December 2025

Financial Forecasts · Investment Strategies · Market Trends · NYSE:JNJ · Pharmaceuticals · Stock Analysis

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached

8 December 2025

Biotech News · Healthcare Policy · Investment Analysis · Pharmaceuticals · Stock Market

Pharmaceuticals News 8 December 2025 - 10 December 2025